Opko Health Stock Surges Over 33% After Strong Earnings Report
On Tuesday, Opko Health (NASDAQ: OPK) saw its stock surge by over 33%, driven by a strong quarterly earnings report that exceeded expectations. The company reported second-quarter revenue of $163.5 million, up 4% year-over-year and well above the analyst consensus estimate of just under $132 million. Opko also significantly narrowed its net loss to $8.4 million ($0.01 per share) from a prior deficit exceeding $148 million. The improvement was largely attributed to strong performance in its pharmaceuticals segment, which saw revenue rise to $89 million due to higher sales and a licensing deal gain of $29.4 million. Meanwhile, diagnostics revenue declined but was impacted by the divestiture of oncology assets last year. Opko also raised its full-year 2026 revenue guidance from $530–$560 million to $560–$585 million, surpassing analyst expectations. The company now appears leaner and more focused after shedding non-core operations. The improved financials and revised guidance have sparked optimism among investors about Opko's potential for profitability in the near future.
